Revista de Hematología

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Revista de Hematología >Year 2016, Issue 2

Pizarro R, Samanez C, Cartolin M, Delgado F
Impact of serum free light chain measurements in diagnosis of monoclonal gammopathies, experience in Peru
Rev Hematol Mex 2016; 17 (2)

Language: Español
References: 23
Page: 99-106
PDF: 345.68 Kb.

Full text


Background: Monoclonal free light chains (FLCs) are important disease biomarkers in patients with plasma cell-proliferative disorders. The increasing scientific evidence that supports clonal diversity and evolution in multiple myeloma highlights the importance of using appropriate laboratory algorithms that could be able to measure intact immunoglobulins or monoclonal free light chains, both at diagnosis and during the follow up of the response to treatment. Particularly in this area, a focus has been set on the utility of serum FLC (sFLC) assays to replace urine electrophoresis for monoclonal FLC measurement. Due to the limited sensitivity and practical disadvantages of urine analysis, the serum-based algorithm of SPE and sFLC has been adopted by many laboratories around the world as a first line screen in patients with suspected monoclonal gammopathies. The advantages are many and the clinical validation has shown to add value to this scheme that has an increasing acceptance in daily laboratory routine worldwide. In this study we evaluate a local population of patients from our institution with plasma cell dyscrasia and we compare different screening algorithms with the aim to simplify and improve the sensitivity of our initial diagnosis scheme for these pathologies, mainly for multiple myeloma patients.
Objetive: To assess the impact of diagnostic sensitivity of the incorporation of serum free light chain to the original algorithm used in our patients with proliferative disorders of cells B in our institution.
Material and Method: A prospective study was done including 102 patients with diagnosis of monoclonal gammopathy, confirmed by bone marrow biopsy. This cohort was conformed by 92 patients from National Institute of Neoplastic Diseases, Lima, Peru, diagnosed with multiple myeloma, 54 (59%) had IgG production, 23 patients (25%) IgA production and two patients (2%) IgD production as main monoclonal protein.
Results: Out of 92 patients diagnosed with multiple myeloma, 12 patients (13% of the total) had exclusive production of light chain (light chains multiple myeloma; six patients κ y six patients λ) and a patient was found with undetectable production of monoclonal protein, so, he was classified a priori as non secretor multipel myeloma, 1%, added then to the group of light chains multiple myeloma due to his protein production; 14% of the total of patients. Electrophoresis of urine proteins and immunofixation were very unefficient, because only evidenced correct results in 39 (42%) patients of the 92 analyzed.
Conclusion: the incorporation of immunoassay of serum light chains to the diagnostic algorithm of the institution allowed to detect two aditional patients, comparing the results with electrophoresis of serum proteins.

Key words: immunoassays of serum light chains, multiple myeloma, diagnosis.


  1. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009;55:1517-1522.

  2. Zamarin D, Giralt S, Landau H, et al. Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation. Bone Marrow Transplant 2013;48:419-424.

  3. Drayson M, Begum G, Basu S, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional- dose chemotherapy in Medical Research Council UK Multiple Myeloma trials. Blood 2006;108:2013-2019.

  4. Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:538-548.

  5. Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: an alternative test to urine Bence Jones proteins when screening for monoclonal gammopathies. Clin Chem 2006;52:1743-1748.

  6. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-680.

  7. Drayson M, Tang LX, Drew R, Mead GP, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2902.

  8. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.

  9. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-491.

  10. Holding S, Spradbery D, Hoole R, et al. Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies. Clin Chem Lab Med 2011;49:83-88.

  11. Fulton RB, Fernando SL. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy. Ann Clin Biochem 2009;46:407-412.

  12. Abadie JM, Bankson DD. Serum free light chain assay in the detection of monoclonal and polyclonal gammopathies in patients with normal serum protein electrophoresis 2006. Ann Clin Lab Sci 2006;36:157-162.

  13. Bakshi NA, Gulbranson R, Garstka D, Bradwell AR, Keren DF. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol 2005;124:214-218.

  14. Robson EJD, Taylor J. Utility of serum free light chain analysis when screening for lymphoproliferative disorders. Lab Med 2009;40:325-329.

  15. Piehler AP, Gulbrandsen N, Kierulf P, Urdal P. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem 2008;54:1823-1830.

  16. Vermeersch P, Van Hoovels L, Delforge M, Mariën G, Bossuyt X. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. Br J Haematol 2008;143:496-502.

  17. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-224.

  18. Fantl D. Argentinean guidelines for MM. SAH 2015.

  19. Hungria V, et al. Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira-2012. Rev Bras Hematol Hemoter 2012;35:201-217.

  20. Costa d. Venezuelan Guidelines for MM. SVH 2013.

  21. Gómez-Almaguer D, Cano-Castellanos R, Limón-Flores A, López-Hernández M y col. Guías mexicanas de diagnóstico y recomendaciones terapéuticas para mieloma múltiple (2009). Rev Hematol 2010;11:40-62.

  22. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348-354.

  23. Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2012;8:43-51.

>Journals >Revista de Hematología >Year 2016, Issue 2

· Journal Index 
· Links 

Copyright 2019